+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Incretin pharmacology: a review of the incretin effect and current incretin-based therapies



Incretin pharmacology: a review of the incretin effect and current incretin-based therapies



Cardiovascular and Hematological Agents in Medicinal Chemistry 10(4): 276-288



Given the demonstrated importance of the incretin effect on the prandial insulin response, augmentation of the incretin effect in people with type 2 diabetes is an important pharmacological approach to glycemic management. In recent years, the use of incretin-based therapies, such as GLP-1 receptor agonists and DPP-4 inhibitors, has increased dramatically due to their demonstrated efficacy, low risk of hypoglycemia when used as monotherapy, and reasonable tolerability. Given their effects on glycemic parameters and the likelihood of aiding in weight loss, GLP-1 receptor agonists provide a unique treatment option for people with type 2 diabetes. Increased clinical experience and study of incretin-based therapies will help answer questions about safety issues that have arisen from post-marketing reports. The potential benefit of incretin-based therapies in the treatment of people with type 2 diabetes and cardiovascular disease is currently an active area of inquiry. While the potential benefits of incretin-based therapies in the arena of cardiovascular risk reduction are promising, results from ongoing outcomes-based studies will help determine the role of these agents in this setting.

(PDF emailed within 1 workday: $29.90)

Accession: 053810380

Download citation: RISBibTeXText

PMID: 22827291


Related references

Incretin Pharmacology A Review of the Incretin Effect and Current Incretin-Based Therapies. 2012

Emerging incretin based therapies for type 2 diabetes: incretin mimetics and DPP-4 inhibitors. Current Diabetes Reviews 4(2): 101-109, 2008

Incretin actions and consequences of incretin-based therapies: lessons from complementary animal models. Journal of Pathology 238(2): 345-358, 2016

Distinguishing among incretin-based therapies. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies. Journal of Family Practice 59(9 Suppl 1): S5-S9, 2010

Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies. Journal of Family Practice 59(9 Suppl 1): S20-S27, 2010

Distinguishing among incretin-based therapies. Glucose-lowering effects of incretin-based therapies. Journal of Family Practice 59(9 Suppl 1): S10-S19, 2010

Incretin and incretin-based therapies. Nihon Rinsho. Japanese Journal of Clinical Medicine 68(5): 931-942, 2010

Incretin-based therapies--review of the physiology, pharmacology and emerging clinical experience. Internal Medicine Journal 41(4): 299-307, 2012

Incretin-based therapies: review of current clinical trial data. American Journal of Medicine 123(3 Suppl): S28-S37, 2010

Inkretinforschung und Inkretin-basierte Diabetestherapie; Incretin research and incretin-based diabetes therapy;. Der Diabetologe 13(7): 474-474, 2017

Incretin-based therapy: how do incretin mimetics and DPP-4 inhibitors fit into treatment algorithms for type 2 diabetic patients?. Best Practice and Research. Clinical Endocrinology and Metabolism 23(4): 513-523, 2009

Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes. Regulatory Peptides 122(3): 209-217, 2004

β-cell function, incretin effect, and incretin hormones in obese youth along the span of glucose tolerance from normal to prediabetes to type 2 diabetes. Diabetes 63(11): 3846-3855, 2014

Comparative Effects of Proximal and Distal Small Intestinal Glucose Exposure on Glycemia, Incretin Hormone Secretion, and the Incretin Effect in Health and Type 2 Diabetes. Diabetes Care 2019, 2019

Incretin receptors in non-neoplastic and neoplastic thyroid C cells in rodents and humans: relevance for incretin-based diabetes therapy. Neuroendocrinology 94(4): 291-301, 2012